(Total Views: 611)
Posted On: 02/04/2021 6:39:14 PM
Post# of 154977
Janet Woodcock did make clear her remarks were about those MABs targeting the virus, a caveat that I hope indicates that other MABs have a different MOA. For a while, I believe, she seemed to be aware of Leronlimab but not its MOA that did not go after the virus.
She is clear on that difference now. I believe she was commenting on the MABs she was responsible for under OWS trialing, the ACTIV ( Accelerating COVID-19 Therapeutic Interventions and Vaccines ) trials. There were five categories of these trials and ACTIV-1 was for immune modulators.
The drugs they chose to trial were not very impressive in my opinion compared to Leronlimab.
She is clear on that difference now. I believe she was commenting on the MABs she was responsible for under OWS trialing, the ACTIV ( Accelerating COVID-19 Therapeutic Interventions and Vaccines ) trials. There were five categories of these trials and ACTIV-1 was for immune modulators.
The drugs they chose to trial were not very impressive in my opinion compared to Leronlimab.
(4)
(0)
